Sensus Healthcare (SRTS) Q1 2026 earnings review
A Painful Customer Transition Obscures Early CPT Code Traction
Sensus Healthcare’s Q1 2026 results look disastrous on the surface, with revenue decelerating 59% YoY to a multi-quarter low of $3.4 million and gross margins collapsing to 29.2%. However, the headline numbers obscure a planned structural transition: sales to their historically largest customer went to zero. Stripping out this concentration drag, core direct revenue actually grew 26% YoY to $3.4 million. The highly anticipated, dedicated CPT reimbursement codes (yielding a ~300% bump per-fraction) finally took effect on January 1. Management claims this is actively boosting the pipeline, but the financial realities of deferred revenue models and lower-margin international shipments are masking any immediate profit tailwinds. The company’s goal of achieving full-year profitability in 2026 now faces a steep, uphill battle.
🐂 Bull Case
Excluding the massive drop-off from the historically largest customer, core sales grew 26% YoY (from $2.7M to $3.4M), proving that the broader dermatology market is expanding its adoption of SRT technology.
With the new CMS dedicated CPT codes active as of January 1 (increasing the per-fraction delivery code by ~300%), physician economics have drastically improved, which is generating stronger sales pipeline activity.
🐻 Bear Case
Gross margins imploded from 52.2% a year ago to 29.2% today, driven by a higher proportion of lower-ASP international shipments and the upfront costs associated with Fair Deal Agreement placements.
Adjusted EBITDA deteriorated to negative $4.2M. At this burn rate, the company's previously stated objective of 2026 full-year profitability looks mathematically improbable without a sudden and massive sales spike.
⚖️ Verdict: 🔴
Bearish. While management successfully de-risked its customer concentration, the sheer magnitude of the gross margin compression and escalating EBITDA losses heavily outweigh the optimistic narrative around pipeline improvements.
Key Themes
Gross Margin Compression Contradicts Profitability Narrative
Despite management's positive narrative regarding a stronger sales pipeline and new reimbursement codes, the actual data is grim: gross margins decelerated violently from 52.2% in 25Q1 to just 29.2% in 26Q1. This severe deterioration is attributed to a product mix shift toward international markets (which carry lower Average Selling Prices) and the upfront capital strain of placing systems under the Fair Deal Agreement (FDA) program, where revenue is recognized slowly over time.
Ripping the Band-Aid Off Customer Concentration
The 59% drop in total quarterly revenue looks disastrous until segmented. Sensus deliberately pivoted away from its historically largest customer, logging zero sales to them this quarter (down from 15 systems in 25Q1). Excluding this legacy customer, core direct revenue actually accelerated 26% YoY, growing from $2.7M to $3.4M. This indicates that direct sales to independent and regional practices are healthy and gaining traction.
The CPT Code Catalyst is Active
The long-awaited dedicated CPT codes for SRT and IG-SRT went live on January 1, 2026. This resulted in an approximately 300% increase in the per-fraction delivery code. Management reports that this newfound reimbursement clarity is drastically shortening the decision-making cycle for prospective customers and accelerating broader customer engagement, serving as the company's primary growth driver for the year.
Recurring Revenue Foundation via FDA Program
Sensus placed 4 systems under its Fair Deal Agreement (FDA) program and rental arrangements this quarter (down from 9 last year). However, underlying utilization is stable, with treatment volumes increasing 8% over the first quarter of 2025. Sensus now has 18 active sites and 9 pending activation, slowly building a predictable recurring revenue floor that aligns with the launch of Sensus Link.
Inventory Backlog Continues to Swell
Inventory on the balance sheet climbed to $16.5 million from $14.6 million at the end of 2025. While Sensus previously justified this buildup as preparation for a post-CPT code demand surge, it currently sits at almost five quarters of revenue (at the current run rate). Tying up this much working capital while Adjusted EBITDA bleeds presents a heightened risk of inventory obsolescence.
Other KPIs
Profitability took a significant step backward, decelerating from negative $2.5 million in 25Q1 to negative $4.2 million today. Despite reductions in S&M and R&D expenses, the collapse in gross profit dollars (down to just $1.0M) crushed the operating leverage.
Cash balance declined by nearly $3.8 million sequentially from $22.1 million at the end of 2025. While maintaining zero debt is a major protective buffer, a sustained burn rate of this magnitude severely limits the runway required to bridge the transition to a recurring revenue model.
Guidance
Reversing. In previous quarters (25Q4), management guided to a full-year 2026 objective of profitability. In the current release, they softened the language to 'driving Sensus toward profitability.' Given the $2.6M net loss and negative $4.2M Adjusted EBITDA in Q1 alone, achieving full-year profitability is highly unlikely unless direct system sales accelerate violently and margins instantly normalize.
Key Questions
Margin Normalization Timeline
Gross margins fell to 29.2% primarily due to international mix and upfront FDA placement costs. At what quarterly system placement volume does management expect margins to revert to the historical 50%+ levels?
Profitability Viability
Management previously stated the objective for full-year 2026 profitability. Following a negative $4.2 million Adjusted EBITDA print in Q1, what exact sequential revenue growth is mathematically required to hit breakeven by year-end?
Working Capital and Inventory
With inventory now sitting at $16.5 million and cash drawing down by $3.8 million in the quarter, are there any plans to slow production until the current backlog is cleared by the anticipated CPT code demand?